Non-Hormonal
Bayer Receives FDA Approval for Lynkuet, a Novel Non-Hormonal Drug for Menopausal Hot Flashes
Bayer; FDA approval; Lynkuet; elinzanetant; hot flashes; menopause; non-hormonal; NK1/NK3 receptors; vasomotor symptoms
Elinzanetant Shows Promise in Reducing Hot Flashes in Women Undergoing Breast Cancer Therapy
Elinzanetant, Vasomotor Symptoms, Breast Cancer, Adjuvant Endocrine Therapy, Hot Flashes, Non-Hormonal Treatment
Elinzanetant Demonstrates Sustained Efficacy Over One Year in Managing Menopausal Vasomotor Symptoms
Elinzanetant, Menopause, Vasomotor Symptoms, Sleep Disturbances, Non-Hormonal Treatment, Bayer